| Jonathan Jay Levin, MD | |
|
18325 N Allied Way, Suite 100, Phoenix, AZ 85054-3105 | |
| (602) 467-4966 | |
| (480) 419-5401 |
| Full Name | Jonathan Jay Levin |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 17 Years |
| Location | 18325 N Allied Way, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144409137 | NPI | - | NPPES |
| ENROLLED | Medicaid | MN | |
| ENROLLED | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 51173 (Minnesota) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Millennium Vision Inc | 1658350236 | 16 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.
Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which Axiogenesis obtains worldwide access to the extensive portfolio of induced pluripotent stem cell technology for iPSC-derived cardiomyocytes and other cell types, pioneered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application at the University of Kyoto, Japan.
› Verified 7 days ago
| Entity Name | Millennium Vision Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184730251 PECOS PAC ID: 1658350236 Enrollment ID: O20040716000751 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.
Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which Axiogenesis obtains worldwide access to the extensive portfolio of induced pluripotent stem cell technology for iPSC-derived cardiomyocytes and other cell types, pioneered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application at the University of Kyoto, Japan.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Jay Levin, MD 18325 N Allied Way, Suite 100, Phoenix, AZ 85054-3105 Ph: (602) 467-4966 | Jonathan Jay Levin, MD 18325 N Allied Way, Suite 100, Phoenix, AZ 85054-3105 Ph: (602) 467-4966 |
News Archive
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.
Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which Axiogenesis obtains worldwide access to the extensive portfolio of induced pluripotent stem cell technology for iPSC-derived cardiomyocytes and other cell types, pioneered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application at the University of Kyoto, Japan.
› Verified 7 days ago
Dr. Christopher M. Fecarotta, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9305 W Thomas Rd Ste 460, Phoenix, AZ 85037 Phone: 602-933-3937 Fax: 602-933-2409 | |
Aileen F Villareal, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 4400 N 32nd St, Ste 280, Phoenix, AZ 85018 Phone: 602-266-6888 Fax: 602-266-6895 | |
Mr. Sharam Danesh, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4045 E Union Hills Dr Ste 115, Phoenix, AZ 85050 Phone: 602-368-3448 Fax: 602-357-3323 | |
Madhavi Kurli, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 19820 N 7th St, Suite 120, Phoenix, AZ 85024 Phone: 480-397-9560 Fax: 480-397-9561 | |
Rima Bharat Patel, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1750 E Glendale Ave, Phoenix, AZ 85020 Phone: 602-242-4928 Fax: 602-249-4813 | |
Daniel Patrick Dansdill, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 4800 N 22nd St Ste 120, Phoenix, AZ 85016 Phone: 602-955-1000 Fax: 602-508-4830 | |
James L Plotnik, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1920 E Cambridge Ave Ste 203, Phoenix, AZ 85006 Phone: 602-933-3937 Fax: 602-933-2409 |